Our ongoing studies will address the possibility that our newly engineered anti‐IL‐13 Rα2 construct will improve tumour specificity and reduce potential for off target effects due to expression of IL‐13 Rα1 on normal tissues. The gene discussed is IL13RA2; the disease is neoplasm.